$1.14 Billion in Sales Expected for Diplomat Pharmacy, Inc. (NYSE:DPLO) This Quarter

Brokerages predict that Diplomat Pharmacy, Inc. (NYSE:DPLO) will announce $1.14 billion in sales for the current quarter, Zacks reports. Six analysts have made estimates for Diplomat Pharmacy’s earnings, with the lowest sales estimate coming in at $1.09 billion and the highest estimate coming in at $1.18 billion. Diplomat Pharmacy posted sales of $1.09 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 4.6%. The firm is scheduled to announce its next earnings results on Tuesday, August 8th.

On average, analysts expect that Diplomat Pharmacy will report full-year sales of $1.14 billion for the current fiscal year, with estimates ranging from $4.40 billion to $4.70 billion. For the next year, analysts anticipate that the firm will post sales of $5.17 billion per share, with estimates ranging from $4.81 billion to $5.39 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Diplomat Pharmacy.

Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, May 8th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.04. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Diplomat Pharmacy had a return on equity of 7.91% and a net margin of 0.38%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the business posted $0.23 EPS.

Several research firms have issued reports on DPLO. Mizuho upped their price objective on shares of Diplomat Pharmacy from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, May 16th. Leerink Swann restated a “market perform” rating and issued a $18.00 price objective (up previously from $16.00) on shares of Diplomat Pharmacy in a research note on Wednesday, May 17th. Bank of America Corporation upped their target price on shares of Diplomat Pharmacy from $17.00 to $18.50 and gave the company a “neutral” rating in a report on Thursday, May 25th. Barclays PLC set a $20.00 target price on shares of Diplomat Pharmacy and gave the company a “buy” rating in a report on Tuesday, May 9th. Finally, Cowen and Company upped their target price on shares of Diplomat Pharmacy from $12.00 to $17.00 and gave the company a “market perform” rating in a report on Tuesday, May 9th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $21.07.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was first posted by [[site]] and is the property of of [[site]]. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at [[permalink]].

Diplomat Pharmacy (NYSE DPLO) traded down 1.44% during trading on Friday, hitting $15.08. The company’s stock had a trading volume of 312,545 shares. The company has a 50-day moving average of $17.70 and a 200 day moving average of $15.30. The firm has a market cap of $1.01 billion, a PE ratio of 60.08 and a beta of 0.64. Diplomat Pharmacy has a one year low of $12.25 and a one year high of $38.94.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Louisiana State Employees Retirement System boosted its position in Diplomat Pharmacy by 0.6% in the second quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the company’s stock valued at $263,000 after buying an additional 100 shares in the last quarter. State of Alaska Department of Revenue boosted its position in Diplomat Pharmacy by 80.0% in the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after buying an additional 3,833 shares in the last quarter. Bank of Montreal Can boosted its position in Diplomat Pharmacy by 3.0% in the second quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock valued at $172,000 after buying an additional 340 shares in the last quarter. Capstone Asset Management Co. boosted its position in Diplomat Pharmacy by 0.5% in the second quarter. Capstone Asset Management Co. now owns 24,430 shares of the company’s stock valued at $362,000 after buying an additional 120 shares in the last quarter. Finally, Redmile Group LLC boosted its position in Diplomat Pharmacy by 718.1% in the first quarter. Redmile Group LLC now owns 1,254,342 shares of the company’s stock valued at $20,007,000 after buying an additional 1,101,025 shares in the last quarter. 72.55% of the stock is owned by hedge funds and other institutional investors.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com